DFDominic Ferber

Dominic Ferber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominic Ferber has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins

    by Bianca Broske, Benjamin A. McEnroe, Sophie C. Frechen, Tim N. Kempchen, Caroline I. Fandrey, Elisabeth Tan, Dominic Ferber, Michelle C. R. Yong, Marie Kleinert, Julia M. Messmer, et al.

    Experimental validation and functional optimization remain bottlenecks in AI-based protein design. We present a scalable workflow for developing AI-designed minibinders against cancer-associated surface proteins. Screening thousands of designs using mammalian cell-surface display identifies several high-affinity PD-L1 minibinders but far fewer for CD276 (B7-H3) and VTCN1 (B7-H4), highlighting substantial target dependence. Interface predicted template modeling (ipTM) scores generated by Chai-1 with ESM embeddings correlate with binding success and capture deleterious effects of interface mutations. Fluorophore-labeled AI-minibinders enable flow-cytometric staining comparable to conventional antibodies. However, when incorporated into chimeric antigen receptors (CAR), some show poor cell-surface trafficking and limited functionality. Redesign through a genetic algorithm-based diversification strategy that preserves the binding interface while changing non-binding surfaces experimentally reveals an isoelectric point (pI) window that improves CAR expression and enhances target-selective tumor cell killing. Our findings identify biochemical optimization beyond the binding interface as a critical requirement for translating AI-minibinders into functional applications.


  • Open Access

    Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

    by Jonas Engelhardt, Nico Kirsch, Aileen Kerfin, Lars P. Lunding, Dominic Ferber, Hannes Buthmann, Ilka Schreier, Carlotta Bosio, Ann‐Kathrin Dobbelstein, Anna Klawonn, et al.

    The NLRP3 inflammasome is a multi‐protein complex that plays a crucial role in inflammatory processes mediated by the innate immune system. Dysregulated NLRP3 activation has been implicated in age‐related inflammatory diseases, making it a promising therapeutic target. Here, we report that the synthetic membrane‐active antimicrobial peptide Pep19‐2.5 directly inhibits NLRP3 inflammasome activation. Through cellular, biophysical, and biochemical analyses, we find that Pep19‐2.5 suppresses NLRP3 inflammasome signaling downstream of NLRP3 activation. Pep19‐2.5 interacts with macrophage membranes, supporting a membrane‐targeting mechanism for its anti‐inflammatory effects. Mechanistically, Pep19‐2.5 binds to phosphatidylinositol (PI)‐containing lipid membranes and dispersed trans‐Golgi network (dTGN) structures, which could potentially affect NLRP3 recruitment to the dTGN. We demonstrate a strong and NLRP3‐dependent induction of IL‐1β secretion from human macrophages by house dust mite (HDM) extract, which can be inhibited by Pep19‐2.5. In line with these findings, therapeutic application of Pep19‐2.5 via the nasal aerosol route reduces IL‐1β levels, eosinophil infiltration in bronchoalveolar lavage and significantly improved lung function in an in vivo HDM‐mouse model of allergic airway inflammation. Our findings highlight the therapeutic potential of targeting NLRP3 activation by the small membrane‐active peptide Pep19‐2.5 for the treatment of NLRP3‐driven inflammatory diseases.

  • Open Access

    Evolutionary algorithms accelerate de novo design of potent Nectin-4-specific cancer biologics

    by Elisabeth Tan, Sophie C. Frechen, Bianca Broske, Julia M. Messmer, Tim N. Kempchen, Benjamin A. McEnroe, Dominic Ferber, Leonie Waluga, Eduard Below, Alexander Hoch, et al.

    Recent advances in AI-based structural biology have made de novo protein binder design increasingly effective, yet performance remains highly target dependent. For instance, the cancer surface antigen Nectin-4, an immunoglobulin-like cell adhesion protein, proved particularly challenging for RFdiffusion-based minibinder generation, yielding substantially fewer high-quality candidates than related targets. To address this bottleneck, we integrated an evolutionary genetic algorithm (GA) with AI-driven design. GA selection with tunable stringency was coupled with diversification via partial diffusion or direct sequence editing, enabling efficient exploration of sequence-structure space and rapid enrichment of promising candidates. This AI-GA pipeline quickly produced large and diverse minibinder panels with very good in silico quality metrics and is compatible with inputs from multiple design algorithms. Pooled, large-scale experimental screening identified highly stable Nectin-4 minibinders with single-digit nanomolar down to subnanomolar affinities. Lead binders were further engineered into Nectin-4-specific flow cytometry detection reagents and potent bispecific T cell engagers, demonstrating functional activity beyond binding. Together, these results show that evolutionary refinement can unlock challenging targets and accelerate de novo protein design for next-generation cancer biologics.


  • Open Access

    Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action

    by Kevin Wilhelmsen, Aditi Deshpande, Sarah Tronnes, Maitriyee Mahanta, Matthew Banicki, Mary Cochran, Samantha Cowdin, Kristen Fortney, George Hartman, Robert E. Hughes, et al.

    The NLRP3 inflammasome is an intracellular protein complex that causes inflammation via the release of IL-1β and pyroptosis. NLRP3 activation is associated with many age-related inflammatory diseases, and NLRP3 inhibition is a promising therapeutic strategy. We previously performed a DNA-encoded library screen to identify novel NLRP3-binding molecules. Herein we describe the characterization of BAL-0028 as a potent and specific inhibitor of NLRP3 signaling. Notably, BAL-0028 is a poor inhibitor of mouse NLRP3 but inhibits human and primate NLRP3 with nanomolar potency. Using cellular and biochemical analyses, we demonstrate that BAL-0028 binds to the NLRP3 NACHT domain at a site that is distinct from the MCC950-binding pocket. Using humanized NLRP3 mice, we show that a derivative of BAL-0028, BAL-0598, inhibits NLRP3 activation in vivo in a peritonitis model. Finally, we demonstrate that both BAL-0028 and BAL-0598 inhibit select hyperactive NLRP3 mutations associated with autoinflammatory diseases more potently than MCC950. BAL-0028 and BAL-0598 thus represent a new modality for NLRP3 inhibition in inflammatory diseases.


  • Open Access

    Inhibition of NLRP3 by a CNS-penetrating indazole scaffold

    by Jane Torp, Dominic Ferber, Hannes Buthmann, Gregor Hagelueken, Aditi Deshpande, George Hartman, Robert E. Hughes, Taiz Salazar, Sarah Tronnes, Assem Duisembekova, et al.

    Low-grade inflammation is a hallmark of ageing and a key cause of age-related impairments and diseases 1 . The NOD-like receptor NLRP3 senses a variety of danger signals and environmental insults, resulting in pro-inflammatory response, inflammasome formation and pyroptosis 2,3 . Its aberrant activation has been linked to many acute and chronic diseases ranging from atherosclerosis to Alzheimer’s disease and cancer, making NLRP3 an attractive therapeutic target 4,5 . Here we report the discovery, characterization, and structure of an indazole-based NLRP3 antagonist, BAL-1516, which potently inhibits inflammasome formation in monocytes and microglia. The cryo-electron microscopy structure of BAL-1516 bound to NLRP3 reveals a previously undescribed compound binding site at a surface groove of the nucleotide-binding domain with contacts to the FISNA and WHD subdomains. The characteristic feature of BAL compound binding is the formation of three hydrogen bonds to the peripheral β-strand of the triple-ATPase; two from the indazole’s nitrogen atoms and a third from the compounds’ linker region. Additional phenyl and thiazole moieties render the compound hydrophobic, allowing excellent blood-brain barrier penetration. The compound binding site is highly specific for NOD-like receptors, and the optimized compound BAL-1516 is able to directly bind mouse NLRP3 despite two conservative residue changes in the binding interface. The BAL compounds represent a first-in-class family of NLRP3 inhibitors, providing a broad design space, including covalent and degradative properties, for the development of NLRP3-directed therapeutics. The innate immune system contains cytosolic proteins that sense cellular stress caused by bacterial, viral and fungal infections or sterile inflammation, to control cellular integrity 2 . NLRP3 is a well-studied member of the nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) that is involved in the activation of the inflammasome, a multiprotein complex that mediates inflammation 6 . Upon detection of stress or pathogen-associated signals, NLRP3 triggers the activation of caspase-1, which leads to the production of pro-inflammatory cytokines such as IL-1β and IL-18, driving inflammatory responses and ultimately pyroptotic cell death. In the context of neuroinflammation, NLRP3 plays a significant role in the pathogenesis of various neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis 7 . Research into targeting NLRP3 signalling with CNS-penetrating molecules holds potential for developing therapeutic strategies to alleviate neuroinflammatory conditions and to slow the progression of neurodegenerative diseases.


  • Open Access

    Development of AI-designed protein binders for detection and targeting of cancer cell surface proteins

    by Bianca Broske, Sophie C. Binder, Benjamin A. McEnroe, Tim N. Kempchen, Caroline I. Fandrey, Julia M. Messmer, Elisabeth Tan, Peter Konopka, Dominic Ferber, Michelle C. R. Yong, et al.

    Artificial intelligence (AI)-based protein design opens new avenues for the rapid generation of new research tools and therapeutics, but experimental validation lags behind the computational design throughput. Here, we present a scalable workflow for the discovery and validation of AI-designed protein binders. Leveraging the RFdiffusion protein design pipeline with a custom filter for stable alpha-helical bundle folds, we construct libraries of thousands of AI-binders against cancer-associated surface proteins. Mammalian cell-surface and phage display screening yield multiple high-affinity PD-L1 binders but fewer hits for CD276 (B7-H3) and VTCN1 (B7-H4), reflecting the target-dependent efficiency of RFdiffusion in generating high-quality designs. Using our experimentally validated AI-designed binder libraries, we benchmark freely available structure prediction models. We find that interface predicted template modelling (ipTM) scores by Chai-1 with ESM embedding correlate well with experimental success and even predict deleterious effects of binding interface mutations. To demonstrate the versatility of AI-binders as research tools, we deploy them in CAR-T cells and also assemble them with fluorophore-labeled streptavidin into tetravalent quattrobinders, which achieve antibody-comparable staining of endogenous PD-L1 by flow cytometry. With high production yields and accessible structural models, AI-designed quattrobinders are versatile and cost-effective research tools amenable to community-driven validation and optimization.


  • Degrading the key component of the inflammasome: development of an NLRP3 PROTAC

    by Tim Keuler, Dominic Ferber, Jonas Engelhardt, Christian Steinebach, Nico Kirsch, Michael Marleaux, Günther Weindl, Matthias Geyer, Michael Gütschow

    This study explores PROTACs for NLRP3, the key player in innate immunity. We utilised a thiophene analogue of the NLRP3 inhibitor MCC950 and employed CuAAC chemistry for the assembly of PROTACs bearing various linkers and recruiting three different E3 ligases. Compounds were evaluated in bidirectional thermal stability studies with NLRP3 and E3 ligases. IL-1β release and protein abundance of NLRP3 were assessed in cellular assays. PROTAC V2 induces a significant VHL-dependent degradation of NLRP3 and constitutes a valuable tool to decipher the intricate details of the NLRP3 inflammasome.


  • Open Access

    Degrading the key component of the inflammasome: Development of an NLRP3 PROTAC

    by Tim Keuler, Dominic Ferber, Jonas Engelhardt, Christian Steinebach, Michael Marleaux, Günther Weindl, Matthias Geyer, Michael Gütschow

    This study explores PROTACs for NLRP3, the key player in innate immunity. We utilized a thiophene analogue of the NLRP3 inhibitor MCC950 and employed CuAAC chemistry for the assembly of PROTACs bearing various linkers and recruiting three different E3 ligases. Compounds were evaluated in bidirectional thermal stability studies with NLRP3 and E3 ligases. IL-1β release and protein abundance of NLRP3 were assessed in cellular assays. PROTAC V2 induces a significant VHL-dependent degradation of NLRP3 and constitutes a valuable tool to decipher the intricate details of the NLRP3 inflammasome.

  • Open Access

    Two Tags in One Probe: Combining Fluorescence‐ and Biotin‐based Detection of the Trypanosomal Cysteine Protease Rhodesain

    by Carina Lemke, Adéla Jílková, Dominic Ferber, Annett Braune, Anja On, Patrick Johe, Alena Zíková, Tanja Schirmeister, Michael Mareš, Martin Horn, et al.

    Rhodesain is the major cysteine protease of the protozoan parasite Trypanosoma brucei and a therapeutic target for sleeping sickness, a fatal neglected tropical disease. We designed, synthesized and characterized a bimodal activity‐based probe that binds to and inactivates rhodesain. This probe exhibited an irreversible mode of action and extraordinary potency for the target protease with a kinac/Ki value of 37,000 M−1s−1. Two reporter tags, a fluorescent coumarin moiety and a biotin affinity label, were incorporated into the probe and enabled highly sensitive detection of rhodesain in a complex proteome by in‐gel fluorescence and on‐blot chemiluminescence. Furthermore, the probe was employed for microseparation and quantification of rhodesain and for inhibitor screening using a competition assay. The developed bimodal rhodesain probe represents a new proteomic tool for studying Trypanosoma pathobiochemistry and antitrypanosomal drug discovery.